Clinical significance of first‐trimester chorionic bumps: a matched case–control study

Y. Sana,A. Appiah,A. Davison,Kypros H. Nicolaides,Jemma Johns,Jackie Ross

DOI: https://doi.org/10.1002/uog.12528

2013-11-01

Ultrasound in Obstetrics and Gynecology

Abstract:To determine the clinical significance of a chorionic bump diagnosed by ultrasound in women attending an early pregnancy unit in a teaching hospital.

What problem does this paper attempt to address?

Sepsis-associated acute kidney injury - treatment standard.

J. Koyner,A. Zarbock,L. Forni,H. Gómez,P. Pickkers

DOI: https://doi.org/10.1093/ndt/gfad142

2023-07-03

Abstract:Sepsis is a host's deleterious response to infection, which could lead to life-threatening organ dysfunction. Sepsis-associated acute kidney injury (SA-AKI) is the most frequent organ dysfunction and is associated with increased morbidity and mortality. Sepsis contributes to approximately 50% of all AKI in critically ill adult patients. A growing body of evidence has unveiled key aspects of the clinical risk factors, pathobiology, response to treatment, and elements of renal recovery that have advanced our ability to detect, prevent, and treat SA-AKI. Despite these advancements, SA-AKI remains a critical clinical condition and a major health burden, and further studies are needed to diminish the short and long-term consequences of SA-AKI. We review the current treatment standards and discuss novel developments in the pathophysiology, diagnosis, outcome prediction, and management of SA-AKI.

Medicine
Timing of Initiation of Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury

José Agapito Fonseca,Joana Gameiro,Filipe Marques,José António Lopes

DOI: https://doi.org/10.3390/jcm9051413

IF: 3.9

2020-05-10

Journal of Clinical Medicine

Abstract:Sepsis-associated acute kidney injury (SA-AKI) is a major issue in medical, surgical and intensive care settings and is an independent risk factor for increased mortality, as well as hospital length of stay and cost. SA-AKI encompasses a proper pathophysiology where renal and systemic inflammation play an essential role, surpassing the classic concept of acute tubular necrosis. No specific treatment has been defined yet, and renal replacement therapy (RRT) remains the cornerstone supportive therapy for the most severe cases. The timing to start RRT, however, remains controversial, with early and late strategies providing conflicting results. This article provides a comprehensive review on the available evidence on the timing to start RRT in patients with SA-AKI.

medicine, general & internal
Sepsis-Associated Acute Kidney Injury: Where Are We Now?

Dimitris Kounatidis,Natalia G Vallianou,Sotiria Psallida,Fotis Panagopoulos,Evangelia Margellou,Dimitrios Tsilingiris,Irene Karampela,Theodora Stratigou,Maria Dalamaga

DOI: https://doi.org/10.3390/medicina60030434

2024-03-06

Abstract:Worldwide, sepsis is a well-recognized cause of death. Acute kidney injury (AKI) may be related to sepsis in up to 70% of AKI cases. Sepsis-associated AKI (SA-AKI) is defined as the presence of AKI according to the Kidney Disease: Improving Global Outcomes criteria in the context of sepsis. SA-AKI is categorized into early, which presents during the first 48 h of sepsis, and late, presenting between 48 h and 7 days of sepsis. SA-AKI is associated with a worse prognosis among patients with sepsis. However, there are different SA-AKI phenotypes as well as different pathophysiological pathways of SA-AKI. The aim of this review is to provide an updated synopsis of the pathogenetic mechanisms underlying the development of SA-AKI as well as to analyze its different phenotypes and prognosis. In addition, potential novel diagnostic and prognostic biomarkers as well as therapeutic approaches are discussed. A plethora of mechanisms are implicated in the pathogenesis of SA-AKI, including inflammation and metabolic reprogramming during sepsis; various types of cell death such as apoptosis, necroptosis, pyroptosis and ferroptosis; autophagy and efferocytosis; and hemodynamic changes (macrovascular and microvascular dysfunction). Apart from urine output and serum creatinine levels, which have been incorporated in the definition of AKI, several serum and urinary diagnostic and prognostic biomarkers have also been developed, comprising, among others, interleukins 6, 8 and 18, osteoprotegerin, galectin-3, presepsin, cystatin C, NGAL, proenkephalin A, CCL-14, TIMP-2 and L-FABP as well as biomarkers stemming from multi-omics technologies and machine learning algorithms. Interestingly, the presence of long non-coding RNAs (lncRNAs) as well as microRNAs (miRNAs), such as PlncRNA-1, miR-22-3p, miR-526b, LncRNA NKILA, miR-140-5p and miR-214, which are implicated in the pathogenesis of SA-AKI, may also serve as potential therapeutic targets. The combination of omics technologies represents an innovative holistic approach toward providing a more integrated view of the molecular and physiological events underlying SA-AKI as well as for deciphering unique and specific phenotypes. Although more evidence is still necessary, it is expected that the incorporation of integrative omics may be useful not only for the early diagnosis and risk prognosis of SA-AKI, but also for the development of potential therapeutic targets that could revolutionize the management of SA-AKI in a personalized manner.
Biomarkers, Diagnosis and Management of Sepsis-Induced Acute Kidney Injury: a Narrative Review.

Zhongheng Zhang

2015-01-01

Abstract:Sepsis is a leading cause of acute kidney injury in clinical practice. The diagnosis of sepsis-induced acute kidney injury requires the diagnosis of sepsis and subsequent occurrence of acute kidney injury. The current definition for acute kidney injury is based on Scr and urine output, which is limited by the delayed identification of such patients. Numerous novel biomarkers have been found to be up-regulated in kidney injury, among which cystatin C and neutrophil gelatinase-associated lipocalin are the most studied. In the management of sepsis-induced acute kidney injury, early goal directed therapy may be potentially useful, but requires further validation in large clinical trials. It is well known that fluid overload is harmful in septic patients with established acute kidney injury and should be avoided. Renal replacement therapy is the mainstay treatment for the severe form of sepsis-induced acute kidney injury. However, there is still no consensus on the definition of timing and dosing in clinical practice, and the optimal timing and dosing are still unknown.
Recent advances in the pharmacological management of sepsis-associated acute kidney injury

Kambiz Kalantari,Mitchell H Rosner

DOI: https://doi.org/10.1080/17512433.2021.1978287

2021-09-14

Expert Review of Clinical Pharmacology

Abstract:Acute kidney injury is a common occurrence in patients with sepsis and portends a high mortality as well as increased morbidity with numerous sequelae including the development of chronic kidney disease. Currently, there are no specific therapies that either prevent AKI or hasten its recovery. Thus, clinicians typically rely on management of the underlying infection, optimization of hemodynamic parameters as well as avoidance of nephrotoxins to maximize outcomes.Recent advances in understanding the mechanisms of sepsis as well as how these pathways may interact to lead to acute kidney injury have opened the door to the development of new, targeted therapies. This review focuses on the operative pathways in sepsis that have been identified as critical in leading to acute kidney injury and associated therapeutic agents that target these pathways.Despite increased understanding of the pathogenesis of sepsis, development of effective therapeutics to decrease the incidence of AKI have lagged. This is likely due to the complex pathophysiology with overlapping pathways and need for multiple therapies guided by specific biomarkers. Biomarkers that detail operative pathways may be able to guide the institution of more specific therapies with the hope for improved outcomes.

pharmacology & pharmacy
Case report 243. Cortical ossifying lipoma of femur.

E. Downey,A. Brower,R. B. Holt

Skeletal Radiology

Abstract:
Human Recombinant Alkaline Phosphatase: a Promising, Yet-to-be-tested Agent for the Treatment Sepsis-Induced Acute Kidney Injury.

Zhongheng Zhang

DOI: https://doi.org/10.21037/atm.2018.12.17

IF: 3.616

2018-01-01

Annals of Translational Medicine

Abstract:Sepsis is defined as an organ dysfunction syndrome caused by the over-activation of inflammatory response (1,2). Kidney is one of the most commonly involved organs in sepsis, and there is a large body of evidence showing that even mild increase in serum creatinine contributes to significantly increased risk of death (3,4). Thus, strenuous efforts have been made to improve renal function during sepsis, including the avoidance of renal toxic agents, treatment with sodium bicarbonate to correct metabolic acidosis (5), and restriction of chloride-rich fluid and starch (3,6,7). However, the risk of acute kidney injury (AKI) is still high in the intensive care unit and a substantial number of patients requires renal replacement therapy to avoid life-threatening metabolic derangements.
Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup

Alexander Zarbock,Mitra K. Nadim,Peter Pickkers,Hernando Gomez,Samira Bell,Michael Joannidis,Kianoush Kashani,Jay L. Koyner,Neesh Pannu,Melanie Meersch,Thiago Reis,Thomas Rimmelé,Sean M. Bagshaw,Rinaldo Bellomo,Vicenzo Cantaluppi,Akash Deep,Silvia De Rosa,Xose Perez-Fernandez,Faeq Husain-Syed,Sandra L. Kane-Gill,Yvelynne Kelly,Ravindra L. Mehta,Patrick T. Murray,Marlies Ostermann,John Prowle,Zaccaria Ricci,Emily J. See,Antoine Schneider,Danielle E. Soranno,Ashita Tolwani,Gianluca Villa,Claudio Ronco,Lui G. Forni

DOI: https://doi.org/10.1038/s41581-023-00683-3

IF: 42.439

2023-02-24

Nature Reviews Nephrology

Abstract:Sepsis-associated acute kidney injury (SA-AKI) is common in critically ill patients and is strongly associated with adverse outcomes, including an increased risk of chronic kidney disease, cardiovascular events and death. The pathophysiology of SA-AKI remains elusive, although microcirculatory dysfunction, cellular metabolic reprogramming and dysregulated inflammatory responses have been implicated in preclinical studies. SA-AKI is best defined as the occurrence of AKI within 7 days of sepsis onset (diagnosed according to Kidney Disease Improving Global Outcome criteria and Sepsis 3 criteria, respectively). Improving outcomes in SA-AKI is challenging, as patients can present with either clinical or subclinical AKI. Early identification of patients at risk of AKI, or at risk of progressing to severe and/or persistent AKI, is crucial to the timely initiation of adequate supportive measures, including limiting further insults to the kidney. Accordingly, the discovery of biomarkers associated with AKI that can aid in early diagnosis is an area of intensive investigation. Additionally, high-quality evidence on best-practice care of patients with AKI, sepsis and SA-AKI has continued to accrue. Although specific therapeutic options are limited, several clinical trials have evaluated the use of care bundles and extracorporeal techniques as potential therapeutic approaches. Here we provide graded recommendations for managing SA-AKI and highlight priorities for future research.

urology & nephrology
[Sigmoid colon cancer during the course of a patient with multiple myeloma (IgG Kappa)].

Y. Iizuka,T. Sugiyama,T. Fuzita,T. Takanashi,T. Suzuki,Y. Kosaka,J. Murakami,T. Shindo,I. Amaki

1983-05-01

Abstract:
Epigenetic Mechanisms in Sepsis-Associated Acute Kidney Injury

Marco Fiorentino,Reginald Philippe,Carmen A. Palumbo,Stefania Prenna,Vincenzo Cantaluppi,Silva De Rosa

DOI: https://doi.org/10.1055/s-0044-1789240

2024-09-01

Seminars in Respiratory and Critical Care Medicine

Abstract:Sepsis, the dysregulated immune response of the host to infections, leads to numerous complications, including multiple organ dysfunction with sepsis-associated acute kidney injury (SA-AKI) being a frequent complication associated with increased risk of mortality and the progression toward chronic kidney disease (CKD). Several mechanisms have been widely investigated in understanding the complex pathophysiology of SA-AKI, including hemodynamic alterations, inflammation, oxidative stress, and direct cellular injury driven by pathogens or cell-derived products (pathogen-associated molecular patterns and damage-associated molecular patterns). Despite advancements in the management of septic patients, the prognosis of SA-AKI patients remains significantly poor and is associated with high in-hospital mortality and adverse long-term outcomes. Therefore, recent research has focused on the early identification of specific SA-AKI endotypes and subphenotypes through epigenetic analysis and the use of potential biomarkers, either alone or in combination with clinical data, to improve prognosis. Epigenetic regulation, such as DNA methylation, histone modifications, and noncoding RNA modulation, is crucial in modulating gene expression in response to stress and renal injury in SA-AKI. At the same time, these modifications are dynamic and reversible processes that can alter gene expression in several pathways implicated in the context of SA-AKI, including inflammation, immune response, and tolerance status. In addition, specific epigenetic modifications may exacerbate renal damage by causing persistent inflammation or cellular metabolic reprogramming, leading to progression toward CKD. This review aims to provide a comprehensive understanding of the epigenetic characteristics that define SA-AKI, also exploring targeted therapies that can improve patient outcomes and limit the chronic progression of this syndrome. Article published online: 29 August 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

respiratory system,critical care medicine
Human recombinant alkaline phosphatase: a promising, yet-to-be-tested agent for the treatment sepsis-induced acute kidney injury

Zhongheng Zhang

DOI: https://doi.org/10.21037/atm.2018.12.17

IF: 3.616

2018-01-01

Annals of Translational Medicine

Abstract:Sepsis is defined as an organ dysfunction syndrome caused by the over-activation of inflammatory response (1,2). Kidney is one of the most commonly involved organs in sepsis, and there is a large body of evidence showing that even mild increase in serum creatinine contributes to significantly increased risk of death (3,4). Thus, strenuous efforts have been made to improve renal function during sepsis, including the avoidance of renal toxic agents, treatment with sodium bicarbonate to correct metabolic acidosis (5), and restriction of chloride-rich fluid and starch (3,6,7). However, the risk of acute kidney injury (AKI) is still high in the intensive care unit and a substantial number of patients requires renal replacement therapy to avoid life-threatening metabolic derangements.
Immunoregulatory mechanism of acute kidney injury in sepsis: A Narrative Review

Shujun Sun,Rui Chen,Xiaoke Dou,Maosha Dai,Junhao Long,Yan Wu,Yun Lin

DOI: https://doi.org/10.1016/j.biopha.2022.114202

2023-01-08

Abstract:Sepsis acute kidney injury (SAKI) is a common complication of sepsis, accounting for 26–50 % of all acute kidney injury (AKI). AKI is an independent risk factor for increased mortality risk in patients with sepsis. The excessive inflammatory cascade reaction in SAKI is one of the main causes of kidney damage. Both the innate immune system and the adaptive immune system are involved in the inflammation process of SAKI. Under the action of endotoxin, neutrophils, monocytes, macrophages, T cells and other complex immune network reactions occur, and a large number of endogenous inflammatory mediators are released, resulting in the amplification and loss of control of the inflammatory response. The study of immune cells in SAKI will help improve the understanding of the immune mechanisms of SAKI, and will lay a foundation for the development of new diagnostic and therapeutic targets. This article reviews the role of known immune mechanisms in the occurrence and development of SAKI, with a view to finding new targets for SAKI treatment.

pharmacology & pharmacy,medicine, research & experimental
Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials

Matthieu Legrand,Sean M. Bagshaw,Pavan K. Bhatraju,Azra Bihorac,Ellen Caniglia,Ashish K. Khanna,John A. Kellum,Jay Koyner,Michael O. Harhay,Fernando G. Zampieri,Alexander Zarbock,Kevin Chung,Kathleen Liu,Ravindra Mehta,Peter Pickkers,Abigail Ryan,Juliane Bernholz,Laura Dember,Martin Gallagher,Patrick Rossignol,Marlies Ostermann

DOI: https://doi.org/10.1186/s13054-024-04877-4

IF: 15.1

2024-03-23

Critical Care

Abstract:Acute kidney injury (AKI) often complicates sepsis and is associated with high morbidity and mortality. In recent years, several important clinical trials have improved our understanding of sepsis-associated AKI (SA-AKI) and impacted clinical care. Advances in sub-phenotyping of sepsis and AKI and clinical trial design offer unprecedented opportunities to fill gaps in knowledge and generate better evidence for improving the outcome of critically ill patients with SA-AKI. In this manuscript, we review the recent literature of clinical trials in sepsis with focus on studies that explore SA-AKI as a primary or secondary outcome. We discuss lessons learned and potential opportunities to improve the design of clinical trials and generate actionable evidence in future research. We specifically discuss the role of enrichment strategies to target populations that are most likely to derive benefit and the importance of patient-centered clinical trial endpoints and appropriate trial designs with the aim to provide guidance in designing future trials.

critical care medicine
Sepsis-associated acute kidney injury in the intensive care unit: incidence, patient characteristics, timing, trajectory, treatment, and associated outcomes. A multicenter, observational study

Kyle C. White,Ary Serpa-Neto,Rod Hurford,Pierre Clement,Kevin B. Laupland,Emily See,James McCullough,Hayden White,Kiran Shekar,Alexis Tabah,Mahesh Ramanan,Peter Garrett,Antony G. Attokaran,Stephen Luke,Siva Senthuran,Philippa McIlroy,Rinaldo Bellomo

DOI: https://doi.org/10.1007/s00134-023-07138-0

IF: 38.9

2023-07-11

Intensive Care Medicine

Abstract:The Acute Disease Quality Initiative (ADQI) Workgroup recently released a consensus definition of sepsis-associated acute kidney injury (SA-AKI), combining Sepsis-3 and Kidney Disease Improving Global Outcomes (KDIGO) AKI criteria. This study aims to describe the epidemiology of SA-AKI.

critical care medicine
The Role of Biomarkers in Diagnosis of Sepsis and Acute Kidney Injury

Gillene Santos Ferreira,Melissa Lopes Frota,Maria José Dias Gonzaga,Maria de Fátima Fernandes Vattimo,Camila Lima

DOI: https://doi.org/10.3390/biomedicines12050931

IF: 4.757

2024-04-24

Biomedicines

Abstract:Sepsis and acute kidney injury (AKI) are two major public health concerns that contribute significantly to illness and death worldwide. Early diagnosis and prompt treatment are essential for achieving the best possible outcomes. To date, there are no specific clinical, imaging, or biochemical indicators available to diagnose sepsis, and diagnosis of AKI based on the KDIGO criterion has limitations. To improve the diagnostic process for sepsis and AKI, it is essential to continually evolve our understanding of these conditions. Delays in diagnosis and appropriate treatment can have serious consequences. Sepsis and AKI often occur together, and patients with kidney dysfunction are more prone to developing sepsis. Therefore, identifying potential biomarkers for both conditions is crucial. In this review, we talk about the main biomarkers that evolve the diagnostic of sepsis and AKI, namely neutrophil gelatinase-associated lipocalin (NGAL), proenkephalin (PENK), and cell-free DNA.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Trends and Outcomes in Sepsis Hospitalizations With and Without Acute kidney injury: A Nationwide Inpatient Analysis

Haibo Li,Ran Yu,Qi Zhou,Jiannan Song,Qi Zhou,Wanli Ma,Jian Wang,Zhanfei Hu,Qinfeng Yang,Keyuan Chen

DOI: https://doi.org/10.1097/shk.0000000000002386

2024-06-11

Shock

Abstract:ABSTRACT BACKGROUND Despite rapid advances in treatment, sepsis currently remains a major public health challenge worldwide. Over the past several years, there has been an increase in the clinical incidence of sepsis, as well as an increase in hospitalization rates, which bear the majority of the economic burden associated with sepsis. Sepsis is a public health burden due to the high fatality rates and accompanying morbidity. However, the sepsis-related mortality rates have fallen steadily over the years. One of the most common organs to fail in patients with sepsis is the kidney, and acute kidney injury(AKI) is associated with high mortality rates. This study's primary goal was to assess the impact of AKI on the evolution and outcome of hospitalization of patients with sepsis. METHODS Adults (≥18 years) hospitalized for sepsis in the United States between 2010 and 2019 were retrospectively analysed using the nationally representative NIS database.Sepsis and acute kidney injury were defined using the codes of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). RESULTS Of the 4,258,360 outcomes, 3,946,048 met the inclusion criteria. The prevalence of AKI among sepsis inpatients increased from 39.10% in 2010 to 41% in 2019, but the impact of AKI on mortality declined over time, with in-hospital mortality from AKI among sepsis inpatients decreasing from 26.30% in 2010 to 16.30% in 2019. Hospitalizations linked to AKI were substantially more likely to involve infection sites such as the urinary tract, gastrointestinal tract, and endocarditis. Numerous pathogenic floras, including Escherichia coli [E. coli], Staphylococcus aureus, Streptococcal, Enterococcus, and Pseudomonas, had greater rates among sepsis-related contacts with AKI. Furthermore, compared to hospitalization without comorbid AKI, the median total hospital charges and length of stay days for sepsis hospitalization with comorbid AKI were greater. CONCLUSIONS With time, patients with sepsis have a higher frequency of AKI and a corresponding decline in mortality.

surgery,peripheral vascular disease,hematology,critical care medicine
Gene Expression Profiling of Sepsis-Associated Acute Kidney Injury

Jing-Juan Yang,Bin-Bin Wu,Fei Han,Jiang-Hua Chen,Yi Yang

DOI: https://doi.org/10.3892/etm.2020.9161

IF: 2.7

2020-01-01

Experimental and Therapeutic Medicine

Abstract:Sepsis accounts for more than 50% of all acute kidney injury (AKI) cases, and the combination of sepsis and AKI increases the risk of mortality from sepsis alone. However, to the best of our knowledge, the specific mechanism by which sepsis causes AKI has not yet been fully elucidated, and there is no targeted therapy for sepsis-associated AKI (SA-AKI). The present study investigated gene expression profiles using RNA sequencing (RNA-Seq) and bioinformatics analyses to assess the function of differentially expressed genes (DEGs) and the molecular mechanisms relevant to the prognosis of SA-AKI. From the bioinformatics analysis, 2,256 downregulated and 3,146 upregulated genes were identified (false discovery rate <0.1 and fold-change >2). Gene Ontology analysis revealed that the genes were enriched in cellular metabolic processes, cell death and apoptosis. The enriched transcription factors were v-rel reticuloendotheliosis viral oncogene homolog A and signaling transducer and activator of transcription 3. The enriched microRNAs (miRNAs or miRs) among the DEGs were miR-30e, miR-181a, miR-340, miR-466d and miR-466l. Furthermore, the enriched pathways included toll-like receptor signaling, nod-like receptor signaling and the Janus kinase/STAT signaling pathway. In conclusion, the present study identified certain prognosis-related genes, transcription factors, miRNAs and pathways by analyzing gene expression profiles of SA-AKI using RNA-Seq, which provides some basis for future experimental studies.
Sepsis‐associated acute kidney injury in patients with chronic kidney disease: Patient characteristics, prevalence, timing, trajectory, treatment and associated outcomes

Kyle C. White,Rinaldo Bellomo,Alexis Tabah,Antony G. Attokaran,Hayden White,James McCullough,Kiran Shekar,Mahesh Ramanan,Peter Garrett,Philippa McIlroy,Siva Senthuran,Stephen Luke,Ary Serpa‐Neto,Tom Larsen,Kevin B. Laupland,the Queensland Critical Care Research Network (QCCRN)

DOI: https://doi.org/10.1111/nep.14392

2024-09-20

Nephrology

Abstract:Aim The features and outcomes of sepsis‐associated acute kidney injury (SA‐AKI) may be affected by chronic kidney disease (CKD). Accordingly, we aimed to compare SA‐AKI in patients with or without CKD. Methods Retrospective cohort study in 12 intensive care units (ICU). We studied the prevalence, patient characteristics, timing, trajectory, treatment and outcomes of SA‐AKI with and without CKD. Results Of 84 240 admissions, 7255 (8.6%) involved patients with CKD. SA‐AKI was more common in patients with CKD (21% vs 14%; p

urology & nephrology
Protocol for a Prospective Observational Study on the Association of Variables Obtained by Contrast-Enhanced Ultrasonography and Sepsis-Associated Acute Kidney Injury

Ning Liu,Zhongheng Zhang,Yucai Hong,Bing Li,Huabo Cai,Hui Zhao,Junru Dai,Lian Liu,Xin Qian,Qicheng Jin

DOI: https://doi.org/10.1136/bmjopen-2018-023981

IF: 3.006

2019-01-01

BMJ Open

Abstract:Introduction Sepsis commonly results in acute kidney injury (AKI), whereas about 50% of AKI cases are due to sepsis. Sepsis-associated acute kidney injury (SA-AKI) increases morbidity and mortality especially among critically ill patients. This study aims to monitor renal microcirculation perfusion during sepsis using contrast-enhanced ultrasonography (CEUS), and to explore whether CEUS is useful for predicting the development of SA-AKI. Methods and analysis This prospective observational study will enrol patients who were diagnosed with sepsis-3 definition. The total of septic or septic shock patients were stratified into AKI (including stages 1, 2 and 3) and non-AKI groups according to Kidney Disease Improving Global Outcomes criteria on days 0, 1, 2 and 7 after admission to the emergency intensive care unit, meanwhile, the CEUS technique will be performed to monitor renal microcirculation perfusion. A multivariable model including all CEUS variables were expected to create for predicting the development of AKI during sepsis. Ultrasonography results, demographic information, therapeutic interventions, survival outcomes, laboratory and other clinical datas will also be collected for further analysis. Ethics and dissemination The study protocol was approved on 2 August 2017 by the Ethics Committee of Sir Run Run Shaw Hospital (Zhejiang University Medical College) (approval number: 2016C91401). The results will be published in a peer-reviewed journal and shared with the worldwide medical community within 2 years after the start of the recruitment. Trial registration number ISRCTN14728986
The role of thromboinflammation in acute kidney injury among patients with septic coagulopathy

Toshiaki Iba,Julie Helms,Cheryl L Maier,Marcel Levi,Ecaterina Scarlatescu,Jerrold H Levy,Cheryl L. Maier,Jerrold H. Levy

DOI: https://doi.org/10.1016/j.jtha.2024.02.006

2024-02-01

Journal of Thrombosis and Haemostasis

Abstract:Inflammation and coagulation are critical self-defense mechanisms for mitigating infection that can nonetheless induce tissue injury and organ dysfunction. In severe cases, like sepsis, a dysregulated thromboinflammatory response may result in multiorgan dysfunction. Sepsis-associated acute kidney injury (AKI) is a significant contributor to patient morbidity and mortality. The connection between AKI and thromboinflammation is largely due to unique aspects of the renal vasculature. Specifically, the interaction between blood cells with the endothelial, glomerular, and peritubular capillary systems during thromboinflammation reduces oxygen supply to tubular epithelial cells. Previous studies have focused on tubular epithelial cell damage due to hypoxia, oxidative stress, and nephrotoxins. Although these factors are pivotal in acute tubular injury or necrosis, recent studies have demonstrated that AKI in sepsis encompasses a mixture of tubular and glomerular damage subtypes. In cases of sepsis-induced coagulopathy, thromboinflammation within the glomerulus and peritubular capillaries is an important pathogenic mechanism for AKI. Unfortunately, and despite the use of renal replacement therapy, the development of AKI in sepsis continues to be associated with high morbidity, mortality, and clinical challenges requiring alternative approaches. This review introduces the important role of thromboinflammation in AKI pathogenesis and details innovative vascular-targeting therapeutic strategies.

peripheral vascular disease,hematology

Clinical significance of first‐trimester chorionic bumps: a matched case–control study

Sepsis-associated acute kidney injury - treatment standard.

Timing of Initiation of Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury

Sepsis-Associated Acute Kidney Injury: Where Are We Now?

Biomarkers, Diagnosis and Management of Sepsis-Induced Acute Kidney Injury: a Narrative Review.

Recent advances in the pharmacological management of sepsis-associated acute kidney injury

Case report 243. Cortical ossifying lipoma of femur.

Human Recombinant Alkaline Phosphatase: a Promising, Yet-to-be-tested Agent for the Treatment Sepsis-Induced Acute Kidney Injury.

Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup

[Sigmoid colon cancer during the course of a patient with multiple myeloma (IgG Kappa)].

Epigenetic Mechanisms in Sepsis-Associated Acute Kidney Injury

Human recombinant alkaline phosphatase: a promising, yet-to-be-tested agent for the treatment sepsis-induced acute kidney injury

Immunoregulatory mechanism of acute kidney injury in sepsis: A Narrative Review

Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials

Sepsis-associated acute kidney injury in the intensive care unit: incidence, patient characteristics, timing, trajectory, treatment, and associated outcomes. A multicenter, observational study

The Role of Biomarkers in Diagnosis of Sepsis and Acute Kidney Injury

Trends and Outcomes in Sepsis Hospitalizations With and Without Acute kidney injury: A Nationwide Inpatient Analysis

Gene Expression Profiling of Sepsis-Associated Acute Kidney Injury

Sepsis‐associated acute kidney injury in patients with chronic kidney disease: Patient characteristics, prevalence, timing, trajectory, treatment and associated outcomes

Protocol for a Prospective Observational Study on the Association of Variables Obtained by Contrast-Enhanced Ultrasonography and Sepsis-Associated Acute Kidney Injury

The role of thromboinflammation in acute kidney injury among patients with septic coagulopathy